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OBJECTIVE—Sirtuins (SIRTs) are NAD
-dependent deacety-
lases that regulate metabolism and life span. We used peripheral
blood mononuclear cells (PBMCs) to determine ex vivo whether
insulin resistance/metabolic syndrome inﬂuences SIRTs. We also
assessed the potential mechanisms linking metabolic alterations
to SIRTs in human monocytes (THP-1) in vitro.
RESEARCH DESIGN AND METHODS—SIRT1-SIRT7 gene
and protein expression was determined in PBMCs of 54 subjects
(41 with normal glucose tolerance and 13 with metabolic syn-
drome). Insulin sensitivity was assessed by the minimal model
analysis. Subclinical atherosclerosis was assessed by carotid
intima-media thickness (IMT). In THP-1 cells exposed to high
glucose or fatty acids in vitro, we explored SIRT1 expression, p53
acetylation, Jun NH2-terminal kinase (JNK) activation, NAD

levels, and nicotinamide phosphoribosyltransferase (NAMPT)
expression. The effects of SIRT1 induction by resveratrol and of
SIRT1 gene silencing were also assessed.
RESULTS—In vivo, insulin resistance and metabolic syndrome
were associated with low PBMC SIRT1 gene and protein expres-
sion. SIRT1 gene expression was negatively correlated with
carotid IMT. In THP-1 cells, high glucose and palmitate reduced
SIRT1 and NAMPT expression and reduced the levels of intra-
cellular NAD
 through oxidative stress. No effect was observed
in cells exposed to linoleate or insulin. High glucose and palmi-
tate increased p53 acetylation and JNK phosphorylation; these
effects were abolished in siRNA SIRT1–treated cells. Glucose-
and palmitate-mediated effects on NAMPT and SIRT1 were
prevented by resveratrol in vitro.
CONCLUSIONS—Insulin resistance and subclinical atheroscle-
rosis are associated with SIRT1 downregulation in monocytes.
Glucotoxicity and lypotoxicity play a relevant role in quenching
SIRT1 expression. Diabetes 59:1006–1015, 2010
M
etabolic syndrome is increasingly prevalent
in the general population. Excess caloric in-
take and nutrient availability are the obvious
culprits that lead to obesity and insulin resis-
tance. In turn, metabolic syndrome predisposes to early
atherosclerosis and cardiovascular morbidity (1). The evo-
lutionary conserved silent information regulator 2 (SIR2)
is a NAD
-dependent deacetylase that regulates life span
in response to caloric restriction in many organisms.
Mammalian homologues of SIR2 comprise a family of
seven proteins termed Sirtuins (SIRT1-SIRT7), which are
implicated in metabolic processes and stress resistance
(2,3). Caloric restriction extends life span in a variety of
organisms through induction of SIRT (4). In mammals,
SIRT1 deacetylates many key transcription factors and
cofactors, such as the tumor suppressor p53, forkhead box
class O (FOXO) proteins (5), peroxisome proliferator–
activated receptor- coactivator-1 (PGC-1) (6), and nu-
clear factor-B (7). These speciﬁc actions may affect
cellular pathways involved in glucose homeostasis. The
effects of SIRT appear to be beneﬁcial, as they trigger
metabolic changes similar to those observed in caloric
restriction. Indeed, calorie restriction increases the levels
of SIRT1 in the liver and muscle, which are key insulin-
sensitive organs (8). Moreover, SIRT1
/ mice are insen-
sitive to the metabolic effects of caloric restriction (9).
In light of these observations, SIRTs have been pro-
posed as a possible target for the treatment of metabolic
syndrome (3,4,10). In white adipose tissue, SIRT1 was
shown to inhibit adipogenesis and to reduce fat storage in
differentiated cells (11). In parallel, pancreatic -cells were
found to be highly enriched in SIRT4: knocking out this
SIRT in insulinoma cells and in mice triggers insulin
hypersecretion (12,13).
Despite this considerable amount of data, no informa-
tion is available on the relationships between insulin
sensitivity and SIRTs in humans, and on the mechanisms
that might potentially interfere with their expression.
Speciﬁcally, there is no demonstration that SIRTs are
altered in the setting of metabolic syndrome, a well-known
condition of insulin resistance.
Thus, we sought to determine whether insulin resis-
tance and metabolic syndrome and its components are
associated with altered SIRT gene and protein expression
in circulating peripheral blood mononuclear cells
(PBMCs). Monocytes play a major role in pathogenetic
processes linked to metabolic syndrome, such as inﬂam-
mation of the adipose tissue and development of the
atherosclerotic plaque (14,15). The use of these cells can
also circumvent ethical concerns inherent to the invasive
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samples. In addition, we aimed to extend the observations
from in vivo studies by investigating the potential mecha-
nisms linking excess nutrient and SIRT in a human mono-
cyte cell line (THP-1).
RESEARCH DESIGN AND METHODS
Subjects. We recruited by advertisement 54 consecutive volunteers who were
employees of the Padova Province Ofﬁces. Their carbohydrate metabolism
status was determined by a standard 75-g oral glucose tolerance test (OGTT)
performed within the previous 6 months. Patients ﬁlled out a complete
lifestyle questionnaire regarding medical history, parental history of cardio-
vascular disease, smoking habits, and physical activity. A physical examina-
tion ruled out peripheral vascular disease by clinical criteria (absence of
peripheral pulses of the lower extremity) and ankle-brachial pressure indexes
0.9. The extent of subclinical atherosclerosis was measured by quantitative
high-resolution B-mode ultrasound of the far wall of the right and left common
carotid arteries. The measurements were carried out as previously reported
according to a validated procedure with an HDI-5000 SONO CT ultrasound
machine (Philips Medical System/ATL Spa) equipped with a phased-array 4- to
7-MHz transducer. Intima-media thickness (IMT) readings were performed
independently by two trained operators as described (16). A resting 12-lead
electrocardiogram was performed, and angina was excluded in each patient
according to the World Health Organization Rose questionnaire. Four subjects
were moderately hypertensive and were on antihypertensive drugs (two
subjects on ACE inhibitors and two on angiotensin receptor blockers). This
therapy was discontinued 3 days before the study. Smoking and alcohol intake
were prohibited at least 24 h before the study. All subjects were following
their standard Italian diet containing at least 50% of carbohydrates as energy.
Human experimental protocol. Each subject was evaluated after overnight
fasting at the Division of Metabolic Diseases, University School of Medicine,
Padova, Italy. The protocol was approved by the Ethics Committee of the
University Hospital of Padova and all subjects provided informed consent.
Anthropometric parameters and multiple blood pressure measurements were
recorded. A cannula was inserted in a superﬁcial vein of the arm for blood
sample collection. Then, a mixed meal containing 10 kcal/kg (55% carbohy-
drate, 15% protein, and 30% fat) was administered in 10–15 min. Plasma
samples were drawn at 5, 0, 10, 20, 30, 60, 90, 120, 150, and 180 min, and
plasma glucose, insulin, C-peptide, and free fatty acid (FFA) concentrations
were determined to evaluate insulin sensitivity index (Si) (17). At baseline,
lipid concentrations were measured as well. Metabolic syndrome was diag-
nosed according to the revised Adult Treatment Panel-III (ATP-III) criteria
(18). At time 0 and 180 min, blood samples were obtained for the isolation of
PBMCs to determine SIRT gene and protein expression.
The analytic methods, preparation of PBMCs, cell culture conditions, assess-
ment of cell viability, quantitative Real Time RT-PCR (Q-PCR) (supplementary
Table 1), Western blot analysis, p53-acetylation procedure, SIRT1 silencing,
measurement of intracellular reactive oxygen species (ROSs), and NAD
 deter-
mination are reported in supplementary methods, available in an online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1187/DC1.
Insulin sensitivity. Insulin sensitivity (deﬁned as Si and expressed as 10
4
dl  kg
1  min
1 per U/ml) was estimated from plasma glucose and insulin
concentrations measured during the meal test using the oral glucose minimal
model (19). Si measures the overall effect of insulin to stimulate glucose
disposal and to inhibit glucose production. The minimal model has been
validated against the hyperinsulinemic-euglycemic clamp, which is considered
the gold standard for assessment of insulin sensitivity. Subjects were divided
into insulin sensitive and insulin resistant according to the median value of Si
(9.5 	 10
4 dl  kg
1  min
1 per U/ml).
Statistical analysis. Statistical analyses were performed with SPSS Version
13.0. Data are presented as mean 
 SE. Normal distribution was veriﬁed with
the Kolmogorov-Smirnov test. Differences between two groups were assessed
using Student t test for unpaired data or Mann-Whitney test for nonnormally
distributed variables. Pearson correlation was used to evaluate univariate
correlations. To assess independent association between SIRT expression and
clinical data, a stepwise multiple regression model was used. A P value  0.05
was accepted as signiﬁcant.
RESULTS
Subjects’ characteristics and metabolic responses. A
total of 13 subjects fulﬁlled ATP-III criteria for diagnosis of
metabolic syndrome. Clinical characteristics of subjects
divided into non–metabolic syndrome and metabolic syn-
drome are presented in Table 1. Upon OGTT, 41 subjects
had normal glucose tolerance (NGT) and 13 had pre-
diabetes. Of these, four had impaired fasting glucose (IFG,
deﬁned as preload plasma glucose 100 mg/dl); nine had
impaired glucose tolerance (IGT, deﬁned as postload
plasma glucose 140 and 200 mg/dl); three had both IFG
and IGT; and none had diabetes.
Glucose and FFA areas under the curve (AUC) were
calculated and stratiﬁed according to insulin sensitivity
and glucose tolerance. Glucose AUC was signiﬁcantly
higher in insulin resistant versus insulin sensitive (10674 

751 vs. 16687 
 782 mg  dl
1  min; P  0.001), in
metabolic syndrome versus non–metabolic syndrome
(21389 
 1,276 vs. 17822 
 634; P  0.01) and in IFG/IGT
versus NGT (22756 
 1,233 vs. 17388 
 562; P  0.001).
The FFA AUC was signiﬁcantly greater in insulin resistant
versus insulin sensitive (50.16 
 2.98 vs. 33.76 
 2.79
mol  l
1  min; P  0.001), marginally signiﬁcant in
IFG/IGT versus NGT (49.69 
 4.59 vs. 39.50 
 2.59; P 
0.059), and similar in metabolic syndrome versus non–
metabolic syndrome (47.74 
 3.66 vs. 40.12 
 2.78). The
characteristics of subjects divided by insulin resistant and
TABLE 1
Demographic and metabolic characteristics of study subjects
Characteristics All (n  54)
Non–metabolic syndrome
(n  41)
Metabolic syndrome
(n  13)
Sex (male/female) 37/17 26/15 11/2
Age (years) 46.0 
 1 45.3 
 1.2 48.0 
 1.5
BMI (kg/m
2) 26.7 
 0.8 24.5 
 0.6 33.7 
 1.1*
Waist (cm) 93.5 
 2.0 88.1 
 1.8 110.8 
 3.1*
Systolic blood pressure (mmHg) 121.7 
 2 118.5 
 2.1 131.6 
 3.7*
Diastolic blood pressure (mmHg) 80.1 
 1.0 78.1 
 1.2 86.2 
 2.8*
Fasting plasma glucose (mg/dl) 85.7 
 2.0 82.1 
 1.6 97.3 
 5.0*
Fasting plasma insulin (U/ml) 10.5 
 1.1 7.3 
 0.8 20.8 
 2.4*
Fasting plasma C-peptide (ng/ml) 1.6 
 0.1 1.4 
 0.1 2.3 
 0.2*
Plasma triglyceride (mg/dl) 120.2 
 12.8 98.2 
 7.7 189.6 
 40.9*
Plasma total cholesterol (mg/dl) 195.7 
 5.0 191.2 
 4.5 209.9 
 10.9
Plasma HDL cholesterol (mg/dl) 49.4 
 2.2 50.8 
 1.8 40.6 
 2.7*
Plasma LDL cholesterol (mg/dl) 126.1 
 4.0 120.6 
 3.9 143.3 
 9.4*
Plasma FFAs (mol/l) 592 
 59 593 
 42 588 
 73
Data are expressed as mean 
 SE. *P  0.05 versus non–metabolic syndrome.
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supplementary Tables 2 and 3.
SIRT gene and protein expression in relation to
metabolic syndrome and insulin sensitivity. When the
subjects were divided into two groups according to the
presence (n  13) or absence (n  41) of metabolic
syndrome, we found signiﬁcantly lower levels of SIRT1
gene expression in metabolic syndrome versus non–meta-
bolic syndrome subjects (0.67 
 0.08 vs. 1.02 
 0.06
comparative cycle threshold [Ct]; P  0.003), whereas
expression of other SIRTs (SIRT2-SIRT7) were not signif-
icantly altered (Fig. 1A). Similarly, when subjects were
divided into insulin sensitive (n  28) and insulin resistant
(n  26) on the basis of median value of their Si, we found
signiﬁcantly lower SIRT1 gene expression in insulin resis-
tant compared with insulin sensitive (0.77 
 0.06 vs.
1.09 
 0.06 Ct; P  0.001), whereas other SIRTs were
unaffected (Fig. 1B). To conﬁrm this result, we analyzed
the protein level of SIRT1 in PBMCs from these subjects
according to metabolic syndrome and insulin sensitivity.
In PBMCs from metabolic syndrome and from insulin-
resistant subjects, SIRT1 protein expression was signiﬁ-
cantly reduced in comparison with non–metabolic
syndrome subjects and with insulin-sensitive subjects
(metabolic syndrome versus non–metabolic syndrome:
0.37 
 0.06 vs. 0.60 
 0.06 arbitrary units; P  0.010;
insulin resistant versus insulin sensitive: 0.42 
 0.04 vs.
0.67 
 0.09; P  0.021; representative blots are reported in
Fig. 1C and D).
Because sex might inﬂuence SIRT1, we repeated analy-
sis for males and females separately and found a similar
trend of SIRT1 reduction in both males and females with
metabolic syndrome or insulin resistance, compared with
non–metabolic syndrome and insulin sensitivity, respec-
tively (supplementary Fig. 1). However caution should be
paid in interpreting these results because the number of
females in the non–metabolic syndrome and insulin-sensi-
tive groups was very limited (n  2).
SIRT1 expression and glucose homeostasis. We then
looked at differences in SIRT1 expression in subjects with
altered glucose metabolism (IFG or IGT). In comparison
with subjects with NGT (n  41), subjects with pre-
diabetes (n  13) had signiﬁcantly lower levels of SIRT1
gene (Fig. 1E) and protein expression (0.39 
 0.05 vs.
0.59 
 0.06 arbitrary units; P  0.022). This signiﬁcant
association between SIRT1 and carbohydrate metabolism
is corroborated by the observation of the direct correla-
tion between SIRT1 gene expression and Si (r  0.47; P 
0.001; Fig. 1F). A quite similar trend of SIRT1 reduction in
pre-diabetic subjects versus subjects with NGT was found
in both males and females (supplementary Fig. 1).
SIRT1 expression in metabolic syndrome cluster and
subclinical atherosclerosis. SIRT1 gene expression was
signiﬁcantly correlated with all parameters that deﬁne
metabolic syndrome and are linked to insulin resistance:
waist circumference (r  0.43; P  0.001), HDL choles-
terol (r  0.38; P  0.007), triglycerides (r  0.34; P 
0.014), systolic blood pressure (r  0.29; P  0.03), and
fasting plasma glucose (r  0.3; P  0.04). To better
describe the relationship between SIRT1 and metabolic
syndrome, we ﬁrst evaluated the association of individual
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FIG. 1. SIRT1-SIRT7 gene and protein expression in PBMCs. Subjects
were ﬁrst divided by the presence/absence of metabolic syndrome and
by insulin-resistant or insulin-sensitive status. A: Q-PCR analysis of
SIRT1-SIRT7 gene expression in PBMCs from metabolic syndrome and
from non–metabolic syndrome subjects. B: Q-PCR analysis of SIRT1-
SIRT7 gene expression in PBMCs from insulin-resistant and from
insulin-sensitive subjects. The relative quantiﬁcation was achieved by
the expression of each gene of interest by housekeeping genes accord-
ing to Ct formula. C and D: Western blot analysis of SIRT1 from
PBMCs of two representative patients with and without metabolic
syndrome or insulin resistance. Densitometric analysis of SIRT1 after
normalization for glyceraldehyde-3-phosphate dehydrogenase in the
whole cohort of subjects is described in the RESULTS section. E: Subjects
were also divided according to OGTT results into subjects with NGT
and pre-diabetic subjects (either IFG or IGT): SIRT1 expression in
subjects with NGT was signiﬁcantly reduced compared with pre-
diabetic subjects (*P < 0.05). Protein expression data are described in
the RESULTS section. F: SIRT1 gene expression was signiﬁcantly directly
correlated with Si. G: Subjects were also divided according to the
presence (black columns) or absence (white columns) of each meta-
bolic syndrome component, as deﬁned by revised ATP-III criteria (*P <
0.05). I: When subjects were divided according to the number of
metabolic syndrome components, SIRT1 expression was progressively
downregulated by increasing number of components (*P < 0.05 vs. 0
components after -correction; ANOVA, P < 0.05). H: Subjects divided
according to metabolic syndrome and insulin sensitivity: in nine sub-
jects without metabolic syndrome classiﬁed as insulin resistant, there
was a signiﬁcant SIRT1 downregulation compared with insulin-sensi-
tive subjects. *P < 0.05. J: Negative signiﬁcant correlation between
SIRT1 gene expression and maximal carotid IMT. Data are expressed
as mean  SE.
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ATP-III deﬁnition and SIRT1 gene expression. We found
that each metabolic syndrome component was associated
with a signiﬁcant reduction of SIRT1 gene expression (Fig.
1G). Furthermore, when the level of SIRT1 expression was
plotted against the number of metabolic syndrome com-
ponents in each subject, there was a trend of SIRT1
downregulation with components clustering. Compared
with subjects with no component, SIRT1 downregulation
was statistically signiﬁcant after -adjusting when at least
three components were present together, allowing the
diagnosis of metabolic syndrome (Fig. 1I). Interestingly,
among patients without metabolic syndrome, those be-
longing to the insulin-resistant group showed a signiﬁcant
SIRT1 downregulation compared with insulin-sensitive
subjects (Fig. 1H). To further clarify these associations,
we ran a stepwise multiple regression analysis, which
showed that age and the number of metabolic syndrome
components were signiﬁcantly correlated with SIRT1 gene
expression independently of sex, of all the parameters that
deﬁne metabolic syndrome components and Si (supple-
mentary Table 4).
Finally, as metabolic syndrome components are known
cardiovascular risk factor, we looked for an association
between SIRT1 downregulation and carotid IMT, a marker
of early atherosclerosis: we found a signiﬁcant negative
correlation between SIRT1 gene expression and maximal
carotid IMT (Fig. 1J).
SIRT1 expression in THP-1 cells. Insulin resistance,
elevated glucose, and systemic FFA levels are signiﬁcant
contributors of the pathophysiological aspects associated
with metabolic syndrome. Furthermore, hepatic SIRT1 is
an important factor in the regulation of glucose and lipid
metabolism (20). Based on these previous data, and in the
light of our in vivo observations, we hypothesized that
high glucose and FFA levels might be involved in the
cellular regulation of SIRT1 expression. Therefore, we
investigated the effects of glucose, insulin, and palmitate
acid in THP-1 cells, in vitro. As shown in Fig. 2A, gene
expression of SIRT1 decreased signiﬁcantly after 24 h of
treatment with 20 mmol/l glucose, reaching the maximal
reduction after 48 h (20 mmol/l mannitol was used as
osmotic control). Consistently, SIRT1 protein level de-
creased signiﬁcantly after 48 h of glucose treatment (Fig.
2B). A similar effect was also induced by 10 mmol/l
glucose (not shown). Fatty acids are potent nutrient
modulators of insulin resistance. Therefore, we incubated
THP-1 cells with representative saturated (palmitate) and
unsaturated (linolenic) fatty acids for 3 and 24 h. Treat-
ment of THP-1 cells for 24 h with palmitate (500 mol/l)
markedly reduced SIRT1 gene (Fig. 2C) and protein (Fig.
2D) expression, whereas no effect was seen in linolenic
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FIG. 2. Effects of glucose and FFAs on SIRT1 gene and protein expression in THP-1 cells. A and B: THP-1 cells were cultured under normal (5.5
mmol/l) or high (20 mmol/l) glucose for 3, 24, and 48 h. SIRT1 gene (A) and protein (B) expression analysis was performed by Q-PCR and Western
blot, respectively. C and D: THP-1 cells were incubated in presence or absence of FFAs (500 mol/l palmitic acid or 500 mol/l linoleic acid) for
3 and 24 h. SIRT1 gene (C) and protein (D) expression analysis was performed by Q-PCR and Western blot, respectively. Data are expressed as
mean of six experiments  SE, *P < 0.05.
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cells with insulin (from 0.1 to 100 nmol/l) did not modify
the expression of SIRT1 (data not shown). Osmotic con-
trol with mannitol (10 or 20 mmol/l) did not produce any
signiﬁcant effect on SIRT protein expression (supplemen-
tary Fig. 2).
Effect of glucose and palmitic acid on p53 acetylation
in THP-1 cells. Previous studies have demonstrated that
high glucose reduced SIRT1 expression leading to in-
creased p53 acetylation (21). Therefore, we measured the
effects of high glucose and palmitate on the acetylation of
p53 in THP-1 cells. As shown in Fig. 3A, high level of
glucose and palmitate increased acetylated p53 in compar-
ison with control cells. To conﬁrm the role of SIRT1 in the
regulation of p53 acetylation induced by high glucose and
palmitate, we knocked down SIRT1 with siRNA in THP-1
cells. As shown in Fig. 3B, SIRT1 protein content was
reduced by 
70%, and the levels of p53 acetylation were
constitutively higher in siRNA SIRT1 cells than in control
cells (Fig. 3C). Then, we treated the cells with resveratrol
(250 mol/l), a known SIRT1 activator, and measured the
level of p53 acetylation in cells exposed to high glucose or
palmitate. As shown in Fig. 3D and E, resveratrol de-
creased p53 acetylation in THP-1 cells treated with high
glucose or palmitate, but not in siRNA SIRT1 cells. These
data show that increased acetylation of p53 by high
glucose and palmitate can be reversed by resveratrol, and
that this effect is SIRT1 dependent.
It is well known that high glucose and fatty acids
generate ROSs in various cells, including monocytes
(22,23). Thus, we evaluated the effects of high glucose and
palmitate on ROS production in THP-1 cells. Both 20
mmol/l glucose and palmitate increased ROS production
and oxidative stress in THP-1 cells, and these effects were
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FIG. 3. Effect of resveratrol on glucose- and palmitate-induced p53 acetylation in THP-1 cells with and without SIRT1 knockdown. A: THP-1 cells
were cultured under normal (5.5 mmol/l) or high (20 mmol/l) glucose for 48 h or with palmitic acid (500 mol/l for 24 h). B and C: THP-1 cells
were transiently transfected with siRNA speciﬁc for SIRT1. SIRT1 expression was evaluated by Q-PCR (B) and Western blot analysis (C). D:
THP-1 cells were also cultured under normal (5.5 mmol/l) or high (20 mmol/l) glucose for 48 h or with palmitic acid (500 mol/l) for 24 h in
presence and absence of resveratrol (250 mol/l) and siRNA SIRT1 cells. The level of p53 acetylation was determined by immunoprecipitation
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expressed as fold increase normalized to control and expressed as mean of three experiments  SE, *P < 0.01.
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an increase of ROSs may regulate SIRT1 protein level, we
treated cells with H2O2 (250 mol/l for 24 h): SIRT1
protein level was decreased and p53 acetylation dramati-
cally increased, although resveratrol attenuated these ef-
fects (Fig. 4C and D).
Effect of glucose and palmitic acid on JNK activation
in THP-1 cells. We investigated the effects of high glucose
and palmitate on the activation of Jun NH2-terminal kinase
(JNK). As shown in Fig. 4E, both high glucose and
palmitate increased JNK phosphorylation. These effects
were attenuated by activating SIRT1 with resveratrol. This
phenomenon was abolished in siRNA SIRT1–treated cells,
suggesting that it is SIRT1 dependent (Fig. 4F).
Effect of high glucose and palmitic acid on NAMPT
expression. Nicotinamide phosphoribosyltransferase
(NAMPT) is the rate-limiting factor in NAD
 biosynthesis,
and SIRT1 protein expression is regulated by the level of
NAD
. Therefore, we tested whether high level of glucose
or palmitate modulates NAMPT expression in THP-1 cells.
Gene expression of NAMPT markedly decreased after 6-h
high glucose and palmitate treatment (Fig. 4G). Accord-
ingly, high glucose and palmitic acid reduced the levels of
intracellular NAD
 in THP-1 cells in comparison with cells
grown at normal level of glucose (Fig. 4H).
DISCUSSION
This set of both in vivo and in vitro studies offers impor-
tant novel insights on the relationship among SIRT1,
insulin resistance, and metabolic syndrome. The major
result from the in vivo study is that gene and protein
expression of SIRT1 in PBMCs is signiﬁcantly reduced in
relation to insulin resistance and metabolic syndrome.
This result is corroborated by the direct correlation be-
tween SIRT1 expression and a dynamic measure of insulin
sensitivity, as well as by the correlation between SIRT1
expression and the number of metabolic syndrome com-
ponents. Although there is considerable disagreement on
the underlying metabolic syndrome pathophysiology, clin-
ical and experimental data support a link between SIRT1
and metabolic syndrome. Interestingly, the only clinical
variable related to SIRT1 beyond metabolic syndrome
components was age, which is physiologically related to
SIRT1 function as a life-span determinant gene.
The link between SIRT1 and glucose homeostasis is
substantiated by the SIRT1 downregulation observed in
subjects with pre-diabetes, compared with subjects with
normal glucose regulation. Thus, the expression of SIRT1
in PBMCs appears as a novel marker of insulin resistance,
metabolic syndrome, and pre-diabetes. Obviously, we can-
not equate that the biological regulation of SIRT1 in
PBMCs parallels that in insulin-sensitive tissues; nonethe-
less, we anticipate that the gene and protein expression of
SIRT1 in PBMCs may represent a potential and novel
pathogenic pathway of metabolic syndrome. In support of
this, a recent study demonstrated that SIRT1 gene expres-
sion in peripheral blood cells of obese subjects was
modulated by caloric restriction, suggesting that SIRT1
may have an important role in different types of tissue
(24,25). Other data from the literature support this view,
because SIRT1 has been suggested to be involved in the
regulation of glucose homeostasis: it controls hepatic
glucose metabolism by interacting with PGC-1, a tran-
scriptional coactivator that controls glucose metabolism
in the liver (6). SIRT1 increases lipolysis (11), stimulates
FOXO and adiponectin gene expression (26), and is di-
rectly involved in intracellular insulin pathways by selec-
tive inhibition of insulin-induced tyrosine phosphorylation
of insulin receptor substrate-2 (27). SIRT1 also improves
insulin sensitivity under insulin-resistant conditions by
repressing protein tyrosine phosphatase-1B (28). Mice
overexpressing SIRT1 on a high-fat diet show lower lipid-
induced inﬂammation along with better glucose tolerance
(29). It should be noted that the systemic effects of SIRT1
may be more complex than expected: for instance, liver-
targeted SIRT1 knockdown was shown to decrease basal
hepatic glucose production and increase hepatic insulin
sensitivity in type 2 diabetic rats (30). This paradoxical
result, compared with other studies (29), is probably
related to the tissue-speciﬁc versus the systemic effects of
SIRT1 modulation, which differ in the regulation of some
soluble mediators, such as adiponectin. Nonetheless,
available experimental data collectively indicate that acti-
vation of SIRT1 may have a potential beneﬁcial role in
humans. These ﬁndings are clinically relevant, because
decreased SIRT1 may be associated with a series of
metabolic events predisposing to a shorter life span, as
shown in experimental animal models. In Zucker fa/fa
rats, hyperinsulinemic-euglycemic clamp studies demon-
strate that SIRT1 activators improve whole-body glucose
homeostasis and insulin sensitivity in adipose tissue, skel-
etal muscle, and liver (31).
Our data suggest that SIRT1 expression is decreased in
subjects who are insulin resistant, speciﬁcally in those
who are glucose intolerant, and particularly in those with
several components of metabolic syndrome. A challenging
hypothesis is that, in these subjects at risk for premature
cardiovascular disease, SIRT1 determines life span and
disease progression. We lend indirect support to this
hypothesis by showing a signiﬁcant negative correlation
between SIRT1 gene expression and carotid IMT, an index
of early atherosclerosis, supporting the hypothesis that
low SIRT1 is proatherogenic. As recently shown by Cardel-
lini et al, SIRT1 may play an important protective role in
vascular biology (32).
Unfortunately, in vivo observations do not allow to
deﬁne cause-effect relationships: thus, it is not clear
whether low SIRT1 expression predisposes to metabolic
syndrome and insulin resistance, plays a role in disease
pathophysiology, or simply is an epiphenomenon of met-
abolic abnormalities. Therefore, an additional aim of the
present study was to test the hypothesis that excessive
substrate availability, such as that present in patients with
metabolic syndrome, may directly inﬂuence SIRT1 in cells
that may be involved in both atherosclerotic plaque for-
mation and visceral fat inﬂammation.
The evidence that glucose and palmitic acid induce
SIRT1 downregulation in THP-1 cells supports a model
whereby biochemical factors acting in the setting of
metabolic syndrome, such as glucose intolerance and
impaired release of free fatty acids, are responsible for
SIRT1 downregulation. Our data demonstrate also that the
mechanisms linking high glucose and palmitate to SIRT1
impairment include reduction of NAMPT expression with
consequent depletion of cellular NAD
 (a SIRT1 activa-
tor), together with increased generation of ROSs. As a
consequence of SIRT1 downregulation in glucose- and
palmitate-treated THP-1 cells, acetylation of p53 increased
signiﬁcantly, an event that is typically followed by tran-
scription-independent proapoptotic signals. In addition,
we show that SIRT1 downregulation leads to activation of
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FIG. 4. Effects of resveratrol on glucose- and palmitate-induced ROS production, p53 acetylation, and JNK activation in THP-1. A and B: THP-1
cells were cultured under normal (5.5 mmol/l) or high (20 mmol/l) glucose for 3, 24, and 48 h (A) or with palmitate (500 mol/l) for 3 and 24 h
in presence and absence of resveratrol (250 mol/l) (B). Intracellular ROS production was quantiﬁed using the ﬂuorescent probe dichlorodi-
hydroﬂuorescein diacetate acetyl ester. C and D: THP-1 cells were treated with H2O2 (250 mol/l for 24 h), in presence and absence of resveratrol.
The level of p53 acetylation was performed by immunoprecipitation followed by an immunoblot against acetylated lysine residues. E: THP-1 cells
were cultured under normal (5.5 mmol/l) or high (20 mmol/l, 48 h) glucose or with palmitate (500 mol/l for 24 h) in presence and absence of
resveratrol (250 mol/l) and in siRNA SIRT1 cells. The level of JNK phosphorylation (p-JNK) was measured by Western blot. F: Densitometric
analysis of p-JNK after normalization for total JNK in THP-1 cells. Data are expressed as p-JNK/JNK normalized to control. G and H: Effects of
high glucose and palmitate on NAMPT expression and NAD
 cellular content: THP-1 cells were cultured under normal (5.5 mmol/l) or high (20
mmol/l) glucose or with palmitate (500 mol/l) for 3, 6, 24, and 48 h. NAMPT expression was expressed as fold change versus the control condition
(5.5 mmol/l glucose and no palmitate) (G). NAD
 was quantiﬁed in THP-1 cells exposed to high glucose (20 mmol/l) or palmitate (500 mol/l)
for 24 h (H). The values are expressed as mean fold increase of 3–6 experiments over control  SE, *P < 0.01 versus basal or control.
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to macrophage inﬁltration into adipose tissue and to
whole-body insulin sensitivity (33). These pathways trig-
gered in monocytes by glucose and palmitate through
SIRT1 downregulation may be important not only in the
pathophysiology of metabolic syndrome but also in terms
of cardiovascular disease. Our ﬁndings testify that the
interaction between fatty acids and SIRT is reciprocal; it
was previously shown that SIRTs are important regulators
of lipid oxidation through activation of the transcriptional
coactivator PGC-1 (6), although almost unknown is the
regulation of SIRT expression by FFAs. Our in vitro study
sheds light on the complex relationship between substrate
availability and SIRT: we speciﬁcally found that a satu-
rated FFA (palmitate) signiﬁcantly decreases SIRT expres-
sion, whereas an unsaturated FFA (linoleate) did not. At
present, we cannot afﬁrm that this in vitro effect takes
place also in vivo. Despite subjects with insulin resistance
having a signiﬁcantly lower suppression of FFA concen-
tration during glucose load, we found no correlation
between SIRT1 expression and FFA AUC. However, we
cannot provide data on FFA plasma composition of our
patients to test the relationship between circulating satu-
rated fatty acids and SIRT expression.
Glucose and palmitate activated the p53 and JNK path-
ways, which have been implicated in both obesity (34,35)
and atherosclerosis (36,37). Even if we cannot deﬁnitely
rule out other pathways linking glucotoxicity and lipotox-
icity to JNK and p53 activation (Fig. 5), SIRT1 appears to
act as a transducer of negative metabolic signals conveyed
by excess nutrients. Moreover, SIRTs are central modula-
tors of signaling networks critical for maintaining vascular
endothelial homeostasis, especially in the setting of diabe-
tes (38–40). Thus, our in vitro studies conﬁrm that SIRT1
could be a potential therapeutic target to improve the
metabolic milieu and prevent cardiovascular complica-
tions. Herein, we demonstrate that resveratrol, a phytoa-
lexin provided with antioxidant properties that is found in
red wine, is able to limit the negative effects of glucose and
palmitate by counteracting SIRT1 downregulation.
We found no alteration of SIRT2, SIRT3, SIRT4, and
SIRT5 in human metabolic syndrome, insulin resistance,
or pre-diabetes in vivo, even if many relationships have
been previously reported between these Sirtuins and met-
abolic disorders. For instance, it was recently shown that
SIRT2, the most abundant Sirtuin in adipocytes, inhibits
differentiation of these cells, promotes adipogenesis
through modulation of FOXO1 activity, and may play a
role in controlling adipose tissue mass and function (41). It
has also been shown that in PBMCs, SIRT2 is responsive to
caloric restriction (42). The lack of difference in SIRT2
expression in our study is related to the fact that caloric
restriction is possibly a major stimulus for the change in
its expression: indeed, our study subjects were all as-
sessed after at least 12 h of fasting, a period that is
probably too short to detect an increase in SIRT2 expres-
sion. We observed a reduction in SIRT6 and SIRT7 expres-
sion in metabolic syndrome, which did not reach
statistical signiﬁcance but deserves further investigation
because SIRT6 has been recently described as a critical
factor in mammalian aging, as its absence creates a
remarkable phenotype in rodents that includes metabolic
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Inflammation
Atherosclerosis
 
M
Metabolic Syndrome
Saturated
fatty acids Glucose
NAMPT NAD+ ROS
Resveratrol SIRT1
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FIG. 5. Proposed mechanism whereby glucose and palmitate downregulate SIRT1 and induce activation and inﬂammation in monocytes. According
to the data presented, high glucose and palmitate impair expression and function of NAMPT, thus reducing cell NAD
 content. As SIRT1 is NAD

dependent, this leads to reduction of expression and activity of SIRT1. In parallel, both high glucose and palmitate promote production of ROSs,
which may themselves reduce SIRT1. SIRT1 downregulation is then responsible for high p53 acetylation and JNK activation, which are related
to cell activation and inﬂammation. All of these pathways can be prevented by the antioxidant resveratrol. We cannot rule out alternative
pathways by which glucose and palmitate activate JNK and p53 independently of SIRT1 (dashed lines).
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(43). Similarly to SIRT2, cellular SIRT6 levels are in-
creased by calorie restriction as well, although it was
shown that this increase appears to result from protein
stabilization rather than augmented gene expression (44).
In conclusion, we provide, for the ﬁrst time in humans,
evidence that insulin resistance and metabolic syndrome
affect SIRT1 gene and protein expression in PBMCs.
Glucose and saturated fatty acids may be implicated in
SIRT1 downregulation through induction of oxidative
stress and depletion of NAD
. Although we cannot trans-
late this observation to insulin-sensitive cells, we hypoth-
esize that this relationship may be true also in tissues that
play a relevant role in determining insulin resistance. In
addition, expression of SIRT1 in circulating blood cells
may represent a novel marker for a disturbed metabolism,
as well as a pathogenic actor in monocyte-mediated ath-
erosclerotic process, through p53 and JNK pathways.
Interestingly, all of these pathways could be prevented by
resveratrol (Fig. 5).
ACKNOWLEDGMENTS
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, Jacobs DR Jr, Wu C,
Saad MF, Szklo M. Insulin resistance, metabolic syndrome, and subclinical
atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabe-
tes Care 2007;30:2951–2956
2. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing
and longevity protein Sir2 is an NAD-dependent histone deacetylase.
Nature 2000;403:795–800
3. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature
2006;444:868–874
4. Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in
diseases of aging? Trends Biochem Sci 2007;32:555–560
5. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y,
McBurney M, Guarente L. Mammalian SIRT1 represses forkhead transcrip-
tion factors. Cell 2004;116:551–563
6. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P.
Nutrient control of glucose homeostasis through a complex of PGC-1alpha
and SIRT1. Nature 2005;434:113–118
7. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW.
Modulation of NF-kappaB-dependent transcription and cell survival by the
SIRT1 deacetylase. EMBO J 2004;23:2369–2380
8. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz
KT, Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes
mammalian cell survival by inducing the SIRT1 deacetylase. Science
2004;305:390–392
9. Chen D, Steele AD, Lindquist S, Guarente L. Increase in activity during
calorie restriction requires Sirt1. Science 2005;310:1641
10. Jiang WJ. Sirtuins: novel targets for metabolic disease in drug develop-
ment. Biochem Biophys Res Commun 2008;373:341–344
11. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De
Oliveira R, Leid M, McBurney MW, Guarente L. Sirt1 promotes fat
mobilization in white adipocytes by repressing PPAR-gamma. Nature
2004;429:771–776
12. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC,
Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G,
Wolberger C, Prolla TA, Weindruch R, Alt FW, Guarente L. SIRT4 inhibits
glutamate dehydrogenase and opposes the effects of calorie restriction in
pancreatic beta cells. Cell 2006;126:941–954
13. Ahuja N, Schwer B, Carobbio S, Waltregny D, North BJ, Castronovo V,
Maechler P, Verdin E. Regulation of insulin secretion by SIRT4, a mito-
chondrial ADP-ribosyltransferase. J Biol Chem 2007;282:33583–33592
14. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova
GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin
Lipidol 1996;7:330–335
15. Odegaard JI, Chawla A. Mechanisms of macrophage activation in obesity-
induced insulin resistance. Nat Clin Pract Endocrinol Metab 2008;4:619–
626
16. Fadini GP, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A, de
Kreutzenberg SV. Peripheral blood CD34KDR endothelial progenitor
cells are determinants of subclinical atherosclerosis in a middle-aged
general population. Stroke 2006;37:2277–2282
17. Dalla Man C, Caumo A, Cobelli C. The oral glucose minimal model:
estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng
2002;49:419–429
18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake
DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, and Blood
Institute, American College of Cardiology Foundation, American Heart
Association. Implications of recent clinical trials for the National Choles-
terol Education Program Adult Treatment Panel III guidelines. Circulation
2004;110:227–239
19. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose
tolerance test minimal model indexes of beta-cell function and insulin
sensitivity. Diabetes 2001;50:150–158
20. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic
response through hepatic sirtuin 1. Proc Natl Acad Sci U S A 2007;104:
12861–12866
21. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1
through a forkhead-dependent pathway. Science 2004;306:2105–2108
22. Thorlaksdottir AY, Jonsson JJ, Tryggvadottir L, Skuladottir GV, Petursdot-
tir AL, Ogmundsdottir HM, Eyfjord JE, Hardardottir I. Positive association
between DNA strand breaks in peripheral blood mononuclear cells and
polyunsaturated fatty acids in red blood cells from women. Nutr Cancer
2007;59:21–28
23. Avogaro A, Pagnin E, Calo ` L. Monocyte NADPH oxidase subunit
p22(phox) and inducible hemeoxygenase-1 gene expressions are increased
in type II diabetic patients: relationship with oxidative stress. J Clin
Endocrinol Metab 2003;88:1753–1759
24. Crujeiras AB, Parra D, Goyenechea E, Martínez JA. Sirtuin gene expression
in human mononuclear cells is modulated by caloric restriction. Eur J Clin
Invest 2008;38:672–678
25. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and
physiology of sirtuins. Nature 2009;460:587–591
26. Pﬂuger PT, Herranz D, Velasco-Miguel S, Serrano M, Tscho ¨p MH. Sirt1
protects against high-fat diet-induced metabolic damage. Proc Natl Acad
S c iUSA2008;105:9793–9798
27. Zhang J. The direct involvement of SirT1 in insulin-induced insulin
receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007;282:
34356–34364
28. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q. SIRT1 improves insulin
sensitivity under insulin-resistant conditions by repressing PTP1B. Cell
Metab 2007;6:307–319
29. Ramsey KM, Mills KF, Satoh A, Imai S. Age-associated loss of Sirt1-
mediated enhancement of glucose-stimulated insulin secretion in beta
cell-speciﬁc Sirt1-overexpressing (BESTO) mice. Aging Cell 2008;7:78–88
30. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, Iwasaki T,
Stark R, Weismann D, Yu XX, Murray SF, Bhanot S, Monia BP, Horvath TL,
Gao Q, Samuel VT, Shulman GI. SirT1 knockdown in liver decreases basal
hepatic glucose production and increases hepatic insulin responsiveness
in diabetic rats. Proc Natl Acad SciUSA2009;106:11288–11293
31. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L,
Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ,
Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Ifﬂand A, Lavu S,
Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal
CH. Small molecule activators of SIRT1 as therapeutics for the treatment
of type 2 diabetes. Nature 2007;450:712–716
32. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S,
Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, Federici M.
TIMP3 is reduced in atherosclerotic plaques from subjects with type 2
diabetes and increased by SirT1. Diabetes 2009;58:2396–2401
33. Blu ¨her M, Bashan N, Shai I, Harman-Boehm I, Tarnovscki T, Avinaoch E,
Stumvoll M, Dietrich A, Klo ¨ting N, Rudich A. Activated Ask1-MKK4-
p38MAPK/JNK stress signaling pathway in human omental fat tissue may
link macrophage inﬁltration to whole-body insulin sensitivity. J Clin
Endocrinol Metab 2009;94:2507–2515
34. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-
terminal kinase pathways in inﬂammation and origin of obesity and
diabetes. Diabetes 2005;54(Suppl. 2):S73–S78
35. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert
PD, Mataki C, Elliott PJ, Auwerx J. Speciﬁc SIRT1 activation mimics low
energy levels and protects against diet-induced metabolic disorders by
enhancing fat oxidation. Cell Metab 2008;8:347–358
36. Mercer J, Bennett M. The role of p53 in atherosclerosis. Cell Cycle
2006;5:1907–1909
SIRT1 AND METABOLIC SYNDROME
1014 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.org37. Sumara G, Belwal M, Ricci R. “Jnking” atherosclerosis. Cell Mol Life Sci
2005;62:2487–2494
38. Potente M, Dimmeler S. NO targets SIRT1: a novel signaling network in
endothelial senescence. Arterioscler Thromb Vasc Biol 2008;28:1577–1579
39. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial
homeostasis. Cell Cycle 2008;7:2117–2122
40. Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, Komuro
I. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler
Thromb Vasc Biol 2009;29:889–894
41. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation
through FoxO1 acetylation/deacetylation. Cell Metab 2007;6:105–114
42. Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in
response to oxidative stress and caloric restriction. Aging Cell 2007;6:505–
514
43. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L,
Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT,
Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frendewey
D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett
JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, Alt FW. Genomic
instability and aging-like phenotype in the absence of mammalian SIRT6.
Cell 2006;124:315–329
44. Kanﬁ Y, Shalman R, Peshti V, Pilosof SN, Gozlan YM, Pearson KJ, Lerrer B,
Moazed D, Marine JC, de Cabo R, Cohen HY. Regulation of SIRT6 protein
levels by nutrient availability. FEBS Lett 2008;582:543–548
S. V. DE KREUTZENBERG AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 1015